Loading...
Loading...
Among the 9 tracked institutional investors we monitor, ASCENDIS PHARMA A/S is held with a combined value of $5.15B across 19,300,865 shares. The largest holder is RA CAPITAL MANAGEMENT, L.P. with a position worth $2.74B (23.83% of their portfolio). 8 funds opened new positions in the most recent quarter. 1 fund reduced its position.
Total Institutional Value
$5.15B
Total Shares Held
19,300,865
Institutional Holders
9
Ranked by estimated dollars moved (share change × implied price). 13F data lags up to 45 days.
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | $2.74B | 29.06% | New |
| 2 | FMR LLC | $945.68M | 0.05% | New |
| 3 | BlackRock, Inc. | $589.94M | 0.01% | New |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | $413.05M | 0.08% | New |
| 5 | PRICE T ROWE ASSOCIATES INC /MD/ | $299.40M | 0.03% | -26.6% |
| 6 | MILLENNIUM MANAGEMENT LLC | $71.14M | 0.03% | New |
| 7 | CITADEL ADVISORS LLC | $36.78M | 0.03% | New |
| 8 | RENAISSANCE TECHNOLOGIES LLC | $31.93M | 0.05% | New |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | $17.74M | 0.03% | New |
As of the latest SEC 13F filings, RA CAPITAL MANAGEMENT, L.P. is the largest institutional holder of ASCENDIS PHARMA A/S with a position worth $2.74B, representing 29.06% of their portfolio. In total, 9 institutional investors hold ASCENDIS PHARMA A/S with a combined value of $5.15B.
In the most recent quarter, 8 funds opened a new position in ASCENDIS PHARMA A/S. Additionally, 1 reduced their positions.
Institutional investors hold $5.15B worth of ASCENDIS PHARMA A/S stock across 9 positions. The largest institutional holder is RA CAPITAL MANAGEMENT, L.P. with $2.74B in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For ASCENDIS PHARMA A/S, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their ASCENDIS PHARMA A/S positions.